Get 20% discount on reports worth US$ 900 or more from Current Partnering (coupon automatically applied in shopping cart). Offer valid till 31st December, 2014.
    Dermatology Partnering Terms and Agreements

    $2,995.00

    Publication ID
    CPA0814178
    Publication Date
    August 1, 2014
    Pages
    942
    Regions Covered
    Publisher

    Provides comprehensive understanding and unprecedented access to the dermatology partnering deals and agreements entered into by the worlds leading healthcare companies.

    Description
    The Dermatology Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter dermatology partnering deals. The majority of deals are discovery, preclinical or development stage whereby the licensee obtains a right or an option right to license the licensors bacterials technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

    This report provides details of the latest dermatology deals and contracts announced in the healthcare sectors.

    Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

    The report includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. The initial chapters of this report provide an orientation of dermatology dealmaking and business activities. Chapter 1 provides an introduction to the report.

    Chapter 2 provides an overview of the trends in dermatology dealmaking since 2009 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

    Chapter 3 provides a review of the leading dermatology deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

    Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of dermatology deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

    Chapter 5 provides comprehensive access to all dermatology deals since 2009 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

    Chapter 6 provides a comprehensive directory of all dermatology partnering deals signed and announced since 2009. The chapter is organized by specific dermatology therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

    In addition, a comprehensive appendix is provided with each report of all dermatology partnering deals signed and announced since 2009. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

    The report also includes numerous tables and figures that illustrate the trends and activities in dermatology partnering and dealmaking since 2009.

    In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of dermatology technologies and products.

    Benefits
    Dermatology Partnering Terms and Agreementsprovides the reader with the following key benefits:

    • In-depth understanding of dental deal trends since 2009
    • Access dental deal headline, upfront, milestone and royalty data
    • Research hundreds of actual contracts between dermatology partner companies
    • Comprehensive access to over 1500 links to actual dermatology deals entered into by the world’s biopharma companies
    • Indepth review of dental deals entered into by the leading fifty bigpharma companies
    • Benchmark the key deal terms companies have agreed in previous deals
    • Identify key terms under which companies partner dermatology opportunities
    • Uncover companies actively partnering dermatology opportunities

    Report scope

    Dermatology Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to dermatology trends and structure of deals entered into by leading companies worldwide.

    Dermatology Partnering Terms and Agreements includes:
    o Trends in dermatology dealmaking in the biopharma industry since 2009
    o Analysis of dermatology deal structure
    o Access to headline, upfront, milestone and royalty data
    o Access to hundreds of dermatology deal contract documents
    o Comprehensive access to over 1500 dermatology deal records
    o The leading dermatology deals by value since 2009
    o Most active dermatology dealmakers since 2009

    In Dermatology Partnering Terms and Agreements, available deals and contracts are listed by:
    o Headline value o Upfront payment value
    o Royalty rate value o Stage of development at signing
    o Deal component type
    o Technology type
    o Specific therapy indication

    Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

    Executive Summary

    Chapter 1 – Introduction

    Chapter 2 – Trends in dermatology dealmaking

    2.1. Introduction
    2.2. Dermatology partnering over the years
    2.3. Big pharma dermatology dealmaking activity
    2.4. Big biotech dermatology dealmaking activity
    2.5. Dermatology partnering by deal type
    2.6. Dermatology partnering by industry sector
    2.7. Dermatology partnering by stage of development
    2.8. Dermatology partnering by technology type
    2.9. Dermatology partnering by specific therapy indication
    2.10. Average deal terms for dermatology
    2.10.1 Dermatology headline values
    2.10.2 Dermatology upfront payments
    2.10.3 Dermatology milestone payments
    2.10.4 Dermatology royalty rates

    Chapter 3 – Leading Dermatology deals

    3.1. Introduction
    3.2. Top dermatology deals by value

    Chapter 4 – Big pharma dermatology deals

    4.1. Introduction
    4.2. How to use big pharma partnering deals
    4.3. Big pharma dermatology partnering company profiles
    Abbott
    Actavis
    Actavis (Acquired by Watson)
    Allergan
    Amgen
    Astellas
    AstraZeneca
    Baxter International
    Bayer
    Bristol-Myers Squibb
    Celgene
    Eli Lilly
    Endo Pharmaceuticals
    Forest Laboratories
    Galderma
    GlaxoSmithKline
    Hospira
    Johnson & Johnson
    Lundbeck
    Menarini
    Merck & Co
    Merck KGaA
    Mitsubishi Tanabe
    Mylan
    Novartis
    Pfizer
    Ranbaxy Laboratories
    Roche
    Sanofi
    Shionogi
    Shire
    Teva
    Valeant
    Warner Chilcott

    Chapter 5 – Big biotech dermatology deals

    5.1. Introduction
    5.2. How to use big biotech partnering deals
    5.3. Bigbiotech dermatology partnering company profiles
    Actelion
    Anika Therapeutics
    Bavarian Nordic
    Cubist
    Emergent BioSolutions
    Galapagos
    Ipsen
    Isis Pharmaceuticals
    Onyx Pharmaceuticals
    Swedish Orphan Biovitrum
    ViroPharma

    Chapter 6 – Dermatology partnering contracts directory

    6.1. Introduction
    6.2. Company A-Z
    6.3. By deal type
    Asset purchase
    Assignment
    Bigpharma outlicensing
    Co-development
    Collaborative R&D
    Co-market
    Contract service
    Co-promotion
    Development
    Distribution
    Equity purchase
    Joint venture
    Licensing
    Litigation
    Loan
    Manufacturing
    Marketing
    Option
    Promotion
    Research
    Settlement
    Sub-license
    Supply
    Termination
    6.4. By stage of development
    Discovery
    Formulation
    Marketed
    Phase I
    Phase II
    Phase III
    Preclinical
    Regulatory
    6.5. By technology type
    Antibiotics
    Antibodies
    Assays
    Biological compounds
    Biomaterials
    Blood products
    Clinical testing
    Devices
    Diagnostics
    DNA probes
    Drug delivery
    Enabling technology
    Equipment
    Genomics
    Natural product
    Oligonucleotide
    Orphan drug
    Peptides
    Processes
    Proteomics
    Recombinant DNA
    Regenerative medicine
    Research services
    Research supplies
    Screening
    Small molecules
    Stem cells

    Chapter 7 – Dermatology dealmaking by therapeutic target

    7.1. Introduction
    7.2. Deals by therapeutic target
    Dermatology

    Appendices

    Appendix 1 – Directory of dermatology deals by company A-Z 2009- 2014
    Appendix 2 – Directory of dermatology deals by deal type 2009- 2014
    Appendix 3 – Directory of dermatology deals by stage of development 2009- 2014
    Appendix 4 – Directory of dermatology deals by technology type 2009- 2014
    Appendix 5 – Partnering resource center
    Online partnering
    Partnering events
    Further reading on dealmaking
    Deal type definitions
    About Wildwood Ventures
    Current Partnering
    Current Agreements
    Recent report titles from CurrentPartnering
    Order Form – Therapy Reports

    Table of figures

    Figure 1: Dermatology partnering since 2009
    Figure 2: Big pharma – top 50 – Dermatology deals 2009 to 2014
    Figure 3: Big pharma dermatology deal frequency – 2009 to 2014
    Figure 4: Big biotech – top 50 – Dermatology deals 2009 to 2014
    Figure 5: Big biotech dermatology deal frequency – 2009 to 2014
    Figure 6: Dermatology partnering by deal type since 2009
    Figure 7: Dermatology partnering by industry sector since 2009
    Figure 8: Dermatology partnering by stage of development since 2009
    Figure 9: Dermatology partnering by technology type since 2009
    Figure 10: Dermatology partnering by specific dermatology therapy target since 2009
    Figure 11: Dermatology deals with a headline value
    Figure 12: Dermatology deal headline value distribution, US$million – discovery stage
    Figure 13: Dermatology deal headline value distribution, US$million – preclinical stage
    Figure 14: Dermatology deal headline value distribution, US$million – phase I stage
    Figure 15: Dermatology deal headline value distribution, US$million – phase II stage
    Figure 16: Dermatology deal headline value distribution, US$million – phase III stage
    Figure 17: Dermatology deal headline value distribution, US$million – regulatory stage
    Figure 18: Dermatology deal headline value distribution, US$million – marketed stage
    Figure 19: Summary median headline value by stage of development, 2009 to 2014
    Figure 20 Dermatology deals with upfront payment values
    Figure 21: Dermatology deal upfront payment distribution, US$million – discovery stage
    Figure 22: Dermatology deal upfront payment distribution, US$million – preclinical stage
    Figure 23: Dermatology deal upfront payment distribution, US$million – phase I stage
    Figure 24: Dermatology deal upfront payment distribution, US$million – phase II stage
    Figure 25: Dermatology deal upfront payment distribution, US$million – phase III stage
    Figure 26: Dermatology deal upfront payment distribution, US$million – regulatory stage
    Figure 27: Dermatology deal upfront payment distribution, US$million – marketed stage
    Figure 28: Summary median upfront payments by stage of development, 2009 to 2014
    Figure 29: Dermatology deals with milestone payments
    Figure 30: Dermatology deal milestone distribution, US$million – discovery stage
    Figure 31: Dermatology deal milestone distribution, US$million – preclinical stage
    Figure 32: Dermatology deal milestone distribution, US$million – phase I stage
    Figure 33: Dermatology deal milestone distribution, US$million – phase II stage
    Figure 34: Dermatology deal milestone distribution, US$million – phase III stage
    Figure 35: Dermatology deal milestone distribution, US$million – regulatory stage
    Figure 36: Dermatology deal milestone distribution, US$million – marketed stage
    Figure 37: Dermatology deals with royalty rates, %
    Figure 38: Dermatology deal royalty rate distribution, US$million – discovery stage
    Figure 39: Dermatology deal royalty rate distribution, US$million – preclinical stage
    Figure 40: Dermatology deal royalty rate distribution, US$million – phase I stage
    Figure 41: Dermatology deal royalty rate distribution, US$million – phase II stage
    Figure 42: Dermatology deal royalty rate distribution, US$million – phase III stage
    Figure 43: Dermatology deal royalty rate distribution, US$million – regulatory stage
    Figure 44: Dermatology deal royalty rate distribution, US$million – marketed stage
    Figure 45: Summary median royalty rate by stage of development, 2009 to 2014
    Figure 46: Top Dermatology deals by value since 2009
    Figure 47: Online partnering resources
    Figure 48: Forthcoming partnering events

    Abbott, Actavis, Watson Pharmaceuticals, Actelion, Allergan, Amgen, Aspen Pharmacare, Astellas, AstraZeneca, Pfizer, Novartis, GSK, Takeda, Bayer, Boehringer Ingelheim

    How to buy market research report?
     

    Process to buy a market research report from us

    Step 1: Select publication license from Publication Type dropdown.
    Step 2: Click Add To Cart button.
    Step 3: The report is added to your cart and you are redirected to cart page.
    Step 4: Enter Coupon Code (if applicable) and click on Apply to order button.
    Step 5: Review your cart and either click on Checkout button to proceed or click on Checkout with PayPal button for Express Checkout. Please note PayPal option is not available for buyers from India.
    Step 6: Enter your E-mail Address and choose your desired Username and Password for a new account or login with your existing account.
    Step 7: Enter your Billing Information.
    Step 8: Choose your Payment Method from either 2Checkout (default option) or PayPal and click on Review order button.
    Step 9: Review your order and click on Submit order button to go to payment gateway and make payments.
    Step 10: You can change your language and currency if you have selected 2Checkout as your payment option. Your billing information is pre-filled, so you can proceed to Payment Method tab.
    Step 11: Enter your Credit/Debit Card details and click Submit Payment button to make payment and complete purchase process.
     
    Please contact us if you need an Invoice or any other information regarding purchase process.

    Do you have more questions related to this market research report after going trhough the description and table of contents?

    We are here to help. Please use the form given below to let us know your questions related to this report.

    Kindly use your official email address and contact number to ensure speedy response.

    CAPTCHA
    This question is for testing whether you are a human visitor and to prevent automated spam submissions.
    2 + 18 =
    Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

    SINGLE USER LICENSE (PDF)

    • This license allows for use of a publication by one person.
    • This person may print out a single copy of the publication.
    • This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
    • This person cannot share the publication (or any information contained therein) with any other person or persons.
    • Unless a Global License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
    • Customers who infringe these license terms are liable for a Global license fee.

     

    SITE USER LICENSE (PDF)*

    • This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
    • These users may print out a single copy of the publication.
    • These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
    • These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
    • Unless a Global License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
    • Customers who infringe these license terms are liable for a Global license fee.

     

    GLOBAL USER LICENSE (PDF)*

    • This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
    • Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
    • These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

    *If Applicable.

    Note: Product cover images are only for representative purpose only and may vary from those shown above.

    Shopping cart

    0 Items $0.00
    Not able to find what you are looking for?
    Call Us
    WHY CHOOSE MARKET RESEARCH REPORTS?
    1
    Trusted By Leaders
    2
    Shop With Confidence
    3
    Customer Centric
    4
    Personalized Solutions
    5
    Secure Checkout

    User login

    Related Market Research Reports

    Clients Who Trust Us

    Orange, Google, Microsoft, Barclays, CassidianIntel, TPG, Elit Net, Cross Business Producers, AcmavolpakB. Braun, Cobham, fiserv, Harris, Wipro, AonAl Meera, Nomura Research Institute, Tata Consultancy Services, Amara Raja, Hiranandani EnergyMunich Re, Lotte Chemical, National Post, First Data